Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Highlights in experimental therapeutics.

Angelika M Burger1

  • 1Department of Pharmacology and Experimental Therapeutics, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA. aburger@som.umaryland.edu

Cancer Letters
|May 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editor's Note: Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin: An Orally Bioavailable Heat Shock Protein 90 Modulator.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate.

Cancer chemotherapy and pharmacology·2013
Same author

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.

Journal of hematology & oncology·2012
Same author

A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells.

Genes & cancer·2011
Same author

Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2011
Same author

Role of the BCA2 ubiquitin E3 ligase in hormone responsive breast cancer.

The open cancer journal·2010
Same journal

An IL-15 fusion with albumin-binding domain boosts Immunotherapy therapy in glioblastoma via FGF-2 competition regulating FGFR1/2.

Cancer letters·2026
Same journal

Stress-adapted cancer-associated fibroblasts as mediators of immunosuppression and therapy resistance.

Cancer letters·2026
Same journal

Aldo-keto Reductase Family 1 Member C3 Suppresses Glioma Progression via Inhibiting Prostaglandin D2-Dependent RhoA/ROCK Signaling.

Cancer letters·2026
Same journal

Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer.

Cancer letters·2026
Same journal

Early-onset lung cancer: etiologic heterogeneity, genomic features, and age-informed clinical management.

Cancer letters·2026
Same journal

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026
See all related articles

Cancer treatment has shifted to targeted therapies. This review highlights three key strategies: targeting telomeres, inhibiting Hsp90, and modulating the ubiquitin-proteasome system to block tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Cancer treatment has evolved from empirical approaches to targeted therapies.
  • Modern anticancer agents aim for tumor-specific targets, minimizing damage to normal cells.
  • Multiple genetic lesions in cancers necessitate complex drug regimens or multi-target agents.

Purpose of the Study:

  • To review emerging concepts in cancer therapy.
  • To highlight strategies targeting key steps in tumor formation (tumorigenesis).
  • To discuss three specific therapeutic approaches: telomere targeting, Hsp90 inhibition, and ubiquitin-proteasome system modulation.

Main Methods:

  • Review of current research and emerging concepts in cancer treatment.
  • Focus on molecular targets and pathways involved in tumorigenesis.

Related Experiment Videos

  • Discussion of three distinct therapeutic strategies.

    • Main Results:

    • Identification of three key therapeutic strategies for cancer treatment.
    • Strategy 1: Targeting the telomere/telomerase complex to combat cancer cell immortality.
    • Strategy 2: Inhibiting the molecular chaperone Hsp90 to block oncogene activation.
    • Strategy 3: Modulating the ubiquitin-proteasome system to stabilize tumor suppressor proteins.

    Conclusions:

    • Targeted therapies represent a paradigm shift in cancer treatment.
    • Blocking key steps in tumorigenesis through specific molecular targets is crucial.
    • Future cancer therapies will likely involve sophisticated drug cocktails or single agents with multiple targets.